MedTrace Logo

Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

NCT07283575 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 497

Last updated 2025-12-16

No results posted yet for this study

Summary

Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer receiving radiotherapy plus SOC with or without PD-1.

Conditions

  • Metastatic Colorectal Cancer ctDNA Surveillance

Interventions

DIAGNOSTIC_TEST

Plasma ctDNA methylation profiling

Plasma ctDNA methylation profiling was performed using an optimized single-tube multiplex mqMSP assay

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2028-10-10
Completion
2030-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07283575 on ClinicalTrials.gov